Drawing 10 of a kind

The deal between Avalon Ventures and GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) to launch up to 10 early stage companies offers the VC a potential return of more than 10x its investment and gives the pharma access to early stage assets that meet its clinical litmus tests.